Work

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Year: 2019

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Blood

DOI: 10.1182/blood-2019-132629

Authors: Saad Z. Usmani, Hang Quach, María-Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, Anita Zahlten-Kumeli, Meletios A. Dimopoulos

Institutions: St Vincent's Hospital Melbourne, Instituto de Investigación Biomédica de Salamanca, Memorial Sloan Kettering Cancer Center, Hôpital Claude Huriez, Hackensack University Medical Center, University Medical Center Hamburg-Eppendorf, Amgen (United States), National and Kapodistrian University of Athens

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2990982958

FWCI: 5.575

Cites:

Cited by: 43

Related to: 10